Chloroplasts—the "light power plants" of plant cells—are increasingly the focus of synthetic biology. These organelles house ...

A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.

Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Remix), a clinical-stage biotechnology company developing small ...

Biogen Inc. ? will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology's (ASN) annual meeting, taking place November 5-9 in ...

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ...

Return on Assets (ROA): Stoke Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.93%, the company may encounter challenges ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

Answer ALS today announced the full release of its comprehensive ALS clinical and multi-omics dataset, marking the culmination of a multi-year research program and a groundbreaking collaboration with ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...